Cotadutide is a balanced GLP-1/glucagon dual agonist which has been shown in phase 2 trials in people with diabetes and obesity to significantly improve and to reduce body weight by 2–3 kg in comparison to placebo [36, 37]. This evidence concerns the gene GLP1R and obesity disorder.